• IGC Pharma’s third-quarter 2026 net loss attributable to common stockholders widened 12% year over year to approximately $2.05 million.
• Revenue climbed 72% year over year to approximately $328,000.
• R&D expenses fell 38% to approximately $1 million, primarily reflecting completion of most CALMA site activation in the first half of 2026.
• Cash totaled approximately $377,000 at September 30, 2026, with access to an undrawn $12 million revolving working capital credit facility, subject to terms.
• CALMA completed enrollment with 170 participants randomized, exceeding its original 146-participant target for the Alzheimer’s agitation trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611090800ACCESSWRNAPR_____1248769) on November 09, 2026, and is solely responsible for the information contained therein.